The 2026 DRC Ebola outbreak is caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense, abbreviated BDBV), one of six recognised species inside the Orthoebolavirus genus. Bundibugyo is the strain that distinguishes this outbreak from the more familiar Zaire ebolavirus outbreaks of the past two decades, and that distinction has direct operational implications: the licensed Ebola countermeasures available in 2026 — the Merck Ervebo vaccine, and the Inmazeb and Ebanga monoclonal antibody therapies — are Zaire-specific and are not licensed for Bundibugyo virus. This page explains what Bundibugyo virus is, what its outbreak history looks like, and why the strain identity matters for the response posture.
What Bundibugyo virus is
Bundibugyo virus was first identified in 2007 during an outbreak in the Bundibugyo District of western Uganda — the geography for which it is named. The virus is a member of the Orthoebolavirus genus, which contains six recognised species:
- Zaire ebolavirus (EBOV) — the most lethal and most frequently reported species, responsible for the 2014–16 West Africa outbreak and the 2018–20 DRC Equateur and 2018–20 Kivu epidemics.
- Sudan ebolavirus (SUDV) — second-most reported, responsible for the 2022 Uganda Sudan virus outbreak.
- Bundibugyo virus (BDBV) — the focus of this page; Uganda 2007, DRC 2012, DRC 2026.
- Reston virus (RESTV) — non-pathogenic in humans; identified in macaques and pigs.
- Tai Forest virus (TAFV) — one documented human case in 1994.
- Bombali virus (BOMV) — identified in bats; no documented human cases.
Historical Bundibugyo outbreaks
The Bundibugyo virus has a short but clinically informative outbreak history:
- Uganda 2007 (Bundibugyo District) — the first identified Bundibugyo outbreak. 149 suspected cases, 37 deaths (CFR ≈ 25%). The Uganda Ministry of Health and CDC field team established the genus assignment and first published the clinical phenotype.
- DRC 2012 (Orientale Province, now part of Ituri) — 36 confirmed and 41 probable cases, 13 confirmed and 23 probable deaths. CFR among PCR-confirmed cases ≈ 36%.
- DRC 2026 (Ituri + North Kivu) — the current outbreak. As of Day 6 of WHO PHEIC: 85 PCR-confirmed cases in DRC + 2 imported confirmed in Uganda, ~750 suspected cases, 177 deaths cumulative.
How Bundibugyo differs from Zaire ebolavirus
The most operationally important distinction between Bundibugyo and Zaire is the case-fatality rate. Historical Bundibugyo CFR runs at roughly 25–40% with supportive care; historical Zaire ebolavirus CFR runs at roughly 50–90% depending on outbreak setting and access to supportive care. Bundibugyo virus disease is therefore typically classified as a "less lethal" Ebola strain, although the absolute lethality remains high and the clinical course is broadly similar.
The second operationally important distinction is the licensed countermeasures pipeline:
- Merck Ervebo (rVSV-ZEBOV) — licensed for Zaire ebolavirus. Cross-protection against Bundibugyo is not established in human trials.
- Inmazeb (REGN-EB3) — a three-monoclonal-antibody cocktail licensed by the US FDA for Zaire ebolavirus. Bundibugyo cross-neutralisation has not been demonstrated in clinical trials.
- Ebanga (ansuvimab) — a single-monoclonal-antibody therapy licensed for Zaire ebolavirus. Bundibugyo activity not established.
Off-label use of these Zaire-targeted countermeasures against Bundibugyo virus disease is a decision being weighed by WHO, the DRC Ministry of Public Health and academic working groups in 2026 — but the published evidence base for such use is thin, and the WHO R&D Blueprint working group on therapeutics meeting on 22 May 2026 instead recommended that two Bundibugyo-targeted monoclonal antibody candidates be prioritised for new clinical trials, and that the antiviral obeldesivir be assessed in a clinical trial as post-exposure prophylaxis for high-risk contacts of confirmed cases.
How the virus is transmitted
Bundibugyo virus transmits through direct contact with the blood, body fluids (vomit, diarrhea, urine, saliva, sweat, semen, breast milk) of an infected symptomatic person or with surfaces contaminated by those fluids, and through unsafe burial practices. Transmission does not occur through casual contact, through the air over long distances, or before symptom onset. The natural reservoir is presumed to be fruit bats, with spillover events into humans through bushmeat or environmental contact in regions with documented bat-human overlap.
Why strain identity matters for the 2026 outbreak
The Bundibugyo identity of the 2026 DRC outbreak has shaped the response posture in three ways. First, the initial laboratory diagnostics in the field targeted Zaire ebolavirus only and returned negative, briefly delaying recognition of the outbreak; INRB Kinshasa identified the Bundibugyo virus only after expanding the diagnostic panel on 14 May. Second, the unavailability of licensed Bundibugyo-specific countermeasures changes the supportive-care backbone of the response, making fluid resuscitation, electrolyte correction and oxygen support the single most important intervention. Third, the WHO R&D Blueprint priorities have shifted toward Bundibugyo-targeted clinical trials of mAbs and obeldesivir PEP, which are now formally on the table after the 22 May Emergency Committee meeting.